Authors:

William Bush

Date Created:

Not specified

Course Title:

Professor:

Not specified

About Paper:

Raloxifene, an FDA approved selective estrogen receptor modulator, has been proven to reduce fracture risk in women experiencing postmenopausal osteoporosis. Raloxifene was shown to increase bone mineralization and bone mass through its interaction with the cell mediated bone generation-reabsorption cycle. The drug, however, reduced clinical fracture events, further than can be explained by the level of increased bone density. Few studies have shown that raloxifene has cell-independent mechanisms to increase fracture strength. Therefore, this project aims to investigate the nanoscale non-cell mediated impact of the drug on the structure- property relationship of and interface between the two base components of bone, the organic collagen matrix and mineralized crystals. Raloxifene has been shown to increase loosely bound water in bone, and the resultant structure-property effects were sought through small and wide-angle x-ray scattering and in-situ tensile testing after bone samples were soaked in raloxifene and control solutions. The effects of raloxifene on the nanoscale structure of bone will further the investigation on cell independent strengthening mechanisms.

Source:

Purdue University / 2023

Topics:

No topics listed

Co-authors:

William Bush